REMARKS

Applicants thank Examiner Natarajan and Supervisory Examiner Helms for their helpful comments conveyed in a telephonic interview with Applicants' attorney on October 30, 2008. The interview was attended by Examiners Natarajan and Helms, and Janet M. MacLeod. No exhibits were shown and no demonstrations were conducted. A proposed amended claim corresponding to Claim 48 as presently amended was discussed. The Examiners indicated that a claim that recites three light chain complementarity determining regions (CDRs) and three heavy chain CDRs would favorably be considered. Agreement was not reached.

Claims 6, 7, 35, 72, 73 and 81 have been amended to correct inadvertent typographical errors. No new matter has been added. Claim 48 has been amended to include the recitations of Claims 49-51. Support for the subject matter of Claim 48 may be found in the specification, for example, at page 28 and Figure 24. Claims 45, 46 and 49-71 have been cancelled without prejudice.

Claim 47 has been indicated to be allowable.

In the Office Action mailed June 4, 2008, Claims 6, 7, 25-29, 31, 35, 45, 46 and 48 have been rejected under 35 U.S.C. §112, first paragraph, as lacking an enabling disclosure for antibodies containing less than three light chain CDRs and three heavy chain CDRs. In the interest of advancing prosecution, Claim 48 has been amended to recite three light chain CDRs and three heavy chain CDRs. Withdrawal of the rejection under 35 U.S.C. §112, first paragraph, is respectfully requested.

Upon indication of allowable subject matter, Applicants request consideration of additional species of anticancer agents and cytotoxic agents in Claims 29-31 and 78-80.

In view of the foregoing comments and amendments, it is respectfully submitted that the present application is in condition for allowance. Entry of this amendment and favorable reconsideration of all pending claims are respectfully requested.

Respectfully submitted,

November 4, 2008

Janet M. MacLeod

Registration No. 35,263

Telephone No.: (212) 895-4206 Facsimile No.: 212-223-4134

CROWELL & MORING LLP Intellectual Property Group P.O. Box 14300 Washington, DC 20044-4300

DCIWDMS: 6577510_1